42 Trials from the Translational Breast Cancer Research Consortium In addition to reviewing actively recruiting trials from the NCI PDQ database, we reviewed both ongoing and completed clinical trials from the Translational Breast Cancer Research Consortium (TBCRC) that were related to MBC[14] . The TBCRC was founded in 2005 and has been funded, in part, by Alliance members: Breast Cancer Research Foundation, Susan G. Komen, and the Avon Foundation. The TBCRC is a collaborative, multi-institution, academic group that conducts innovative and high-impact clinical trials for breast cancer. The TBCRC is composed of 17 clinical sites, 5 core subcommittees, and working groups. Collectively, these groups work together to foster trial development and enrollment in a collegial environment that enhances cross-institutional collaborations. The activity of the TBCRC is of interest because it is an exemplary model of collaboration, accelerating clinical research related to breast cancer and MBC. The collaboration includes 19 leading academic medical centers and principal investigators launching joint trials, recruiting patients together, and sharing valuable tissue sources and samples. Upon analysis, we found that, of the 30 multicenter clinical trials conducted since the inception of the TBCRC in 2005, 15 (50%) either targeted or included MBC patients (see Table 4). Of these 15 trials, 12 were either not yet fully active or closed to accrual. Because our dataset only includes trials that were active or recruiting patients in April and May 2014, these 12 trials are not included, although the 3 active TBCRC trials are included. Across all 15 MBC trials from TBCRC, 17 new drugs or combinations of drugs have been or are being tested.